{"id":126386,"date":"2022-01-15T11:19:55","date_gmt":"2022-01-15T04:19:55","guid":{"rendered":"https:\/\/nawacita.co\/?p=126386"},"modified":"2022-01-15T11:19:55","modified_gmt":"2022-01-15T04:19:55","slug":"bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir","status":"publish","type":"post","link":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/","title":{"rendered":"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir"},"content":{"rendered":"<p><strong>Jakarta, Nawacita<\/strong> &#8211; Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupiravir sebagai obat Covid-19.<\/p>\n<p>Penny Kusumastuti Lukito Kepala BPOM mengatakan, izin tersebut diterbitkan berdasarkan hasil evaluasi uji klinik bersama Tim Ahli Komite Nasional Penilai Obat serta asosiasi klinisi dan Kementerian Kesehatan.<\/p>\n<p>\u201cSetelah melalui evaluasi terhadap data hasil uji klinik bersama dengan Tim Ahli Komite Nasional Penilai Obat serta asosiasi klinisi untuk persetujuan izin penggunaan, BPOM bersama Kementerian Kesehatan terus memantau keamanan penggunaan Molnupiravir di Indonesia,\u201d ujarnya dalam keterangan di Jakarta, Jumat (14\/1\/2022).<\/p>\n<p>Hasil evaluasi dari aspek keamanan, penggunaan Molnupiravir relatif aman dan efek sampingnya bisa ditoleransi.<\/p>\n<p>Efek samping yang paling sering dilaporkan antara lain mual, sakit kepala, mengantuk, nyeri abdomen dan nyeri orofaring.<\/p>\n<p>Kemudian, hasil uji klinik dan non klinik, Molnupiravir tidak menyebabkan gangguan fungsi hati.<\/p>\n<p>\u201cTerkait efikasi, hasil uji klinik fase tiga menunjukkan Molnupiravir bisa menekan risiko orang yang positif Covid-19 dirawat di rumah sakit. Selain itu, Molnupiravir mengurangi risiko kematian sekitar 30 persen pada pasien bergejala sedang, dan 24,9 persen pada pasien bergejala ringan,\u201d imbuhnya.<\/p>\n<p>Lebih lanjut, Penny menyebut Molnupiravir bisa dipakai untuk pengobatan infeksi Covid-19 ringan sampai sedang pada pasien berusia 18 tahun ke atas yang tidak memerlukan oksigen medis, atau berisiko mengalami gejala berat.<\/p>\n<p>Obat berbentuk kapsul 200 miligram itu diberikan dua kali sehari sebanyak empat kapsul selama lima hari.<\/p>\n<p>Tapi, Molnupiravir tidak boleh diberikan untuk perempuan hamil. Sedangkan perempuan usia subur yang tidak hamil harus memakai kontrasepsi selama menjalani terapi obat Molnupiravir.<\/p>\n<p>Penny menjelaskan, Molnupiravir yang mendapat izin penggunaan di Indonesia produksi Hetero Labs Ltd, India, yang didaftarkan PT Amarox Pharma Global.<\/p>\n<p>Sebelumnya, BPOM sudah lebih dulu menerbitkan izin penggunaan darurat untuk beberapa obat untuk terapi penyembuhan Covid-19, di antaranya antibodi monoklonal Regdanvimab, antivirus Remdesivir dan Favipiravir.<\/p>\n<p>Sekadar informasi, Molnupiravir adalah obat antivirus yang dikembangkan Merck Sharp&amp;Dohme. Perusahaan asal Amerika Serikat itu memberikan voluntary licensing ke beberapa produsen di India.<\/p>\n<p>Sebagai upaya menjaga ketersediaan obat Covid-19 dan mendukung kemandirian industri obat dalam negeri, PT Amarox Pharma Global menyiapkan produksi Molnupiravir melalui transfer teknologi di fasilitas produksinya, kawasan Cikarang, Kabupaten Bekasi, Jawa Barat.<\/p>\n<p>Kalau persyaratan Cara Pembuatan Obat yang Baik (CPOB) sudah terpenuhi, produksi lokal Molnupiravir bisa dimulai awal Maret 2022.<\/p>\n<p>ss.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jakarta, Nawacita &#8211; Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupiravir sebagai obat Covid-19. Penny Kusumastuti Lukito Kepala BPOM mengatakan, izin tersebut diterbitkan berdasarkan hasil evaluasi uji klinik bersama Tim Ahli Komite Nasional Penilai Obat serta asosiasi klinisi dan Kementerian Kesehatan. \u201cSetelah melalui evaluasi terhadap data hasil uji [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":126387,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[15857,28669,22683,40630,19127],"class_list":{"0":"post-126386","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nasional","8":"tag-bpom","9":"tag-covid-19","10":"tag-izinkan","11":"tag-molnupiravir","12":"tag-obat"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir - Nawacita<\/title>\n<meta name=\"description\" content=\"Jakarta, Nawacita - Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupira\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir - Nawacita\" \/>\n<meta property=\"og:description\" content=\"Jakarta, Nawacita - Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupira\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/\" \/>\n<meta property=\"og:site_name\" content=\"Nawacita\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-15T04:19:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nawacita.co\/wp-content\/uploads\/2022\/01\/62442-ilustrasi-molnupiravir.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"653\" \/>\n\t<meta property=\"og:image:height\" content=\"366\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"redaksi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nawacit4\" \/>\n<meta name=\"twitter:site\" content=\"@nawacit4\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"redaksi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/\"},\"author\":{\"name\":\"redaksi\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/person\\\/599683af640858fd3b790bc37828ba57\"},\"headline\":\"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir\",\"datePublished\":\"2022-01-15T04:19:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/\"},\"wordCount\":366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/62442-ilustrasi-molnupiravir.jpg\",\"keywords\":[\"BPOM\",\"COVID-19\",\"Izinkan\",\"molnupiravir\",\"Obat\"],\"articleSection\":[\"Nasional\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/\",\"url\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/\",\"name\":\"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir - Nawacita\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/62442-ilustrasi-molnupiravir.jpg\",\"datePublished\":\"2022-01-15T04:19:55+00:00\",\"description\":\"Jakarta, Nawacita - Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupira\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/62442-ilustrasi-molnupiravir.jpg\",\"contentUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/62442-ilustrasi-molnupiravir.jpg\",\"width\":653,\"height\":366,\"caption\":\"Ilustrasi Obat Covid-19 Molnupiravir\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2022\\\/01\\\/15\\\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nawacita.co\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#website\",\"url\":\"https:\\\/\\\/nawacita.co\\\/\",\"name\":\"Nawacita\",\"description\":\"Berita Kementerian, BUMN, Pemerintah dan Politik\",\"publisher\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nawacita.co\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#organization\",\"name\":\"Nawacita\",\"url\":\"https:\\\/\\\/nawacita.co\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Logo-Nawacita-2021.png\",\"contentUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Logo-Nawacita-2021.png\",\"width\":1676,\"height\":422,\"caption\":\"Nawacita\"},\"image\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/nawacitaco-1763136813898723\\\/?ref=aymt_homepage_panel\",\"https:\\\/\\\/x.com\\\/nawacit4\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/person\\\/599683af640858fd3b790bc37828ba57\",\"name\":\"redaksi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"caption\":\"redaksi\"},\"sameAs\":[\"nawacitaportal\",\"https:\\\/\\\/x.com\\\/nawacit4\"],\"url\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/author\\\/redaksi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir - Nawacita","description":"Jakarta, Nawacita - Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupira","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/","og_locale":"en_US","og_type":"article","og_title":"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir - Nawacita","og_description":"Jakarta, Nawacita - Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupira","og_url":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/","og_site_name":"Nawacita","article_publisher":"https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel","article_published_time":"2022-01-15T04:19:55+00:00","og_image":[{"width":653,"height":366,"url":"https:\/\/nawacita.co\/wp-content\/uploads\/2022\/01\/62442-ilustrasi-molnupiravir.jpg","type":"image\/jpeg"}],"author":"redaksi","twitter_card":"summary_large_image","twitter_creator":"@nawacit4","twitter_site":"@nawacit4","twitter_misc":{"Written by":"redaksi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#article","isPartOf":{"@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/"},"author":{"name":"redaksi","@id":"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57"},"headline":"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir","datePublished":"2022-01-15T04:19:55+00:00","mainEntityOfPage":{"@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/"},"wordCount":366,"commentCount":0,"publisher":{"@id":"https:\/\/nawacita.co\/#organization"},"image":{"@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#primaryimage"},"thumbnailUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2022\/01\/62442-ilustrasi-molnupiravir.jpg","keywords":["BPOM","COVID-19","Izinkan","molnupiravir","Obat"],"articleSection":["Nasional"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/","url":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/","name":"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir - Nawacita","isPartOf":{"@id":"https:\/\/nawacita.co\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#primaryimage"},"image":{"@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#primaryimage"},"thumbnailUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2022\/01\/62442-ilustrasi-molnupiravir.jpg","datePublished":"2022-01-15T04:19:55+00:00","description":"Jakarta, Nawacita - Badan Pengawas Obat dan Makanan (BPOM) sudah menerbitkan izin penggunaan darurat (Emergency Use Authorization) Molnupira","breadcrumb":{"@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#primaryimage","url":"https:\/\/nawacita.co\/wp-content\/uploads\/2022\/01\/62442-ilustrasi-molnupiravir.jpg","contentUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2022\/01\/62442-ilustrasi-molnupiravir.jpg","width":653,"height":366,"caption":"Ilustrasi Obat Covid-19 Molnupiravir"},{"@type":"BreadcrumbList","@id":"https:\/\/nawacita.co\/index.php\/2022\/01\/15\/bpom-terbitkan-izin-penggunaan-obat-covid-19-molnupiravir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nawacita.co\/"},{"@type":"ListItem","position":2,"name":"BPOM Terbitkan Izin Penggunaan Obat Covid-19 Molnupiravir"}]},{"@type":"WebSite","@id":"https:\/\/nawacita.co\/#website","url":"https:\/\/nawacita.co\/","name":"Nawacita","description":"Berita Kementerian, BUMN, Pemerintah dan Politik","publisher":{"@id":"https:\/\/nawacita.co\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nawacita.co\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nawacita.co\/#organization","name":"Nawacita","url":"https:\/\/nawacita.co\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nawacita.co\/#\/schema\/logo\/image\/","url":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png","contentUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png","width":1676,"height":422,"caption":"Nawacita"},"image":{"@id":"https:\/\/nawacita.co\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel","https:\/\/x.com\/nawacit4"]},{"@type":"Person","@id":"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57","name":"redaksi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","caption":"redaksi"},"sameAs":["nawacitaportal","https:\/\/x.com\/nawacit4"],"url":"https:\/\/nawacita.co\/index.php\/author\/redaksi\/"}]}},"jetpack_featured_media_url":"https:\/\/nawacita.co\/wp-content\/uploads\/2022\/01\/62442-ilustrasi-molnupiravir.jpg","_links":{"self":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts\/126386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/comments?post=126386"}],"version-history":[{"count":0,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts\/126386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/media\/126387"}],"wp:attachment":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/media?parent=126386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/categories?post=126386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/tags?post=126386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}